Abstract
Historically treated as monomeric polypeptides, G protein-coupled receptors (GPCRs) have been shown to exist and function as constitutively formed dimers or oligomers. The quaternary structure of GPCRs may modulate ligand binding properties through allosteric mechanisms offering new opportunities for drug design by exploiting multivalency. In this context, multivalent ligands versus bivalent-ligands, possessing two binding motifs connected by a linker, have been investigated and have revealed striking differences in their functional properties compared to their monovalent counterparts. These bi-functional drugs, which are able to activate the two protomers in a dimer simultaneously, emerge as novel and promising drugs for a variety of multi-factorial diseases. In this review, key requirements for the successful design and synthesis of GPCR multivalent ligands composed of pharmacophores and a linker will be discussed. We will then focus on the 5-HT4 receptor (5-HT4R), whose ligands emerged as promising drugs for a variety of central nervous disorders. Upon description of biochemical and biophysical evidences of 5-HT4R dimerization, we will present the multivalent ligand approach, which was assisted by molecular docking experiments on the 5-HT4R dimer model.
Keywords: Bivalent ligands, GPCR oligomers, drug design, 5-HT4 receptors, molecular modeling, organic synthesis, BRET screening.
Current Pharmaceutical Design
Title: Multivalent-Based Drug Design Applied to Serotonin 5-HT4 Receptor Oligomers
Volume: 15 Issue: 6
Author(s): Frank Lezoualc'h, Ralf Jockers and Isabelle Berque-Bestel
Affiliation:
Keywords: Bivalent ligands, GPCR oligomers, drug design, 5-HT4 receptors, molecular modeling, organic synthesis, BRET screening.
Abstract: Historically treated as monomeric polypeptides, G protein-coupled receptors (GPCRs) have been shown to exist and function as constitutively formed dimers or oligomers. The quaternary structure of GPCRs may modulate ligand binding properties through allosteric mechanisms offering new opportunities for drug design by exploiting multivalency. In this context, multivalent ligands versus bivalent-ligands, possessing two binding motifs connected by a linker, have been investigated and have revealed striking differences in their functional properties compared to their monovalent counterparts. These bi-functional drugs, which are able to activate the two protomers in a dimer simultaneously, emerge as novel and promising drugs for a variety of multi-factorial diseases. In this review, key requirements for the successful design and synthesis of GPCR multivalent ligands composed of pharmacophores and a linker will be discussed. We will then focus on the 5-HT4 receptor (5-HT4R), whose ligands emerged as promising drugs for a variety of central nervous disorders. Upon description of biochemical and biophysical evidences of 5-HT4R dimerization, we will present the multivalent ligand approach, which was assisted by molecular docking experiments on the 5-HT4R dimer model.
Export Options
About this article
Cite this article as:
Lezoualc'h Frank, Jockers Ralf and Berque-Bestel Isabelle, Multivalent-Based Drug Design Applied to Serotonin 5-HT4 Receptor Oligomers, Current Pharmaceutical Design 2009; 15(6) . https://dx.doi.org/10.2174/138161209787315602
DOI https://dx.doi.org/10.2174/138161209787315602 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Topical Discoveries on Multi-Target Approach to Manage Alzheimer’s Disease
Current Drug Metabolism Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Cellular Toxicity of Mesoporous Silica Nanoparticle in SHSY5Y and BMMNCs Cell
Pharmaceutical Nanotechnology Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Assessment of Glomerular and Tubular Function
Current Pediatric Reviews Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Molecular and Cellular Control of Dendrite Maturation During Brain Development
Current Molecular Pharmacology Novel Strategies and Tools for Enhanced Sensitivity in Routine Biomolecule Analytics
Current Pharmaceutical Analysis Role of Reactive Oxygen Species in Estrogen Dependant Breast Cancer Complication
Anti-Cancer Agents in Medicinal Chemistry Editorial: Exciting Progresses in Stem Cell and Neural Stem Cell Research
Current Molecular Medicine Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Current Alzheimer Research Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Establishment of a Secondary Screening Assay for P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Resolvins: Endogenously-Generated Potent Painkilling Substances and their Therapeutic Perspectives
Current Neuropharmacology Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson’s Disease
Central Nervous System Agents in Medicinal Chemistry Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study
Current Alzheimer Research